Biophysical and Computational Evidence for Ibuprofen Binding to and Inhibition of MARK4
- 1Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia
Abstract
MARK4 is a serine/threonine kinase implicated in neurodegenerative disorders and cancer, making it an attractive target for therapeutic intervention and drug repurposing. In this study, we investigated the inhibition and interaction of ibuprofen with MARK4 using an integrated experimental and computational approach employing steady-state fluorescence and UV-vis spectroscopy, circular dichroism, molecular docking, and molecular dynamics simulations. The ATPase assays showed that ibuprofen produces dose-dependent inhibition of MARK4 ATPase activity. The ATPase activity of MARK4 was inhibited by >93% with an IC50 of 4.02 ± 0.33 µM. The fluorescence titrations demonstrated quenching of MARK4 intrinsic fluorescence upon addition of ibuprofen. The thermodynamic analysis indicated spontaneous binding with favorable entropy and involvement of hydrophobic forces in the binding. The observed reduction in ellipticity suggests alterations in the secondary structure of MARK4 upon ibuprofen binding. The binding energy from docking was obtained as −7.0 kcal/mol. Ibuprofen was docked within the ATP or inhibitor binding site, with two hydrogen bonds. MD simulations confirmed the dynamic stability of the MARK4–ibuprofen complex over 100 ns. The complex retained overall compactness, with nominal increases in RMSD and RMSF relative to the apo protein. The findings demonstrate the potential of ibuprofen to inhibit MARK4 ATPase activity, which may further guide drug discovery.
Related
- Structural and Biophysical Profiling of HLA Class II Mismatches Using AlphaFold 3: A Computational Study
- Integrated Computational and Spectroscopic Analyses to unravel the Role of Cu(II) Coordination in Modulating Doxorubicin-DNA Binding
- State-selective inhibition of alpha-synuclein aggregation by de novo oligomer-binding proteins
- Allosteric inhibition of human mitochondrial ClpP by hijacking the dordaviprone (ONC201) binding site
- Virtual Screening–Derived Computational Lead Candidates for MAO-B Inhibition in Parkinson’s Disease: Pathway-Informed Docking, Molecular Dynamics, DFT and ADMET Evaluation
BibTeX
@article{sarwar2026biophysical,
title = {{Biophysical and Computational Evidence for Ibuprofen Binding to and Inhibition of MARK4}},
author = {Tarique Sarwar and Hajed Obaid A. Alharbi and Suleman Abdullah Almerdasi and Ahmad Almatroudi and Arshad Husain Rahmani},
journal = {Biomolecules},
year = {2026},
month = oct,
doi = {10.3390/biom16111575},
url = {https://www.mdpi.com/2218-273X/16/11/1575},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Biophysical and Computational Evidence for Ibuprofen Binding to and Inhibition of MARK4
AU - Tarique Sarwar
AU - Hajed Obaid A. Alharbi
AU - Suleman Abdullah Almerdasi
AU - Ahmad Almatroudi
AU - Arshad Husain Rahmani
PY - 2026
DA - 2026/10/29
JO - Biomolecules
DO - 10.3390/biom16111575
UR - https://www.mdpi.com/2218-273X/16/11/1575
AB - MARK4 is a serine/threonine kinase implicated in neurodegenerative disorders and cancer, making it an attractive target for therapeutic intervention and drug repurposing. In this study, we investigated the inhibition and interaction of ibuprofen with MARK4 using an integrated experimental and computational approach employing steady-state fluorescence and UV-vis spectroscopy, circular dichroism, molecular docking, and molecular dynamics simulations. The ATPase assays showed that ibuprofen produces dose-dependent inhibition of MARK4 ATPase activity. The ATPase activity of MARK4 was inhibited by >93% with an IC50 of 4.02 ± 0.33 µM. The fluorescence titrations demonstrated quenching of MARK4 intrinsic fluorescence upon addition of ibuprofen. The thermodynamic analysis indicated spontaneous binding with favorable entropy and involvement of hydrophobic forces in the binding. The observed reduction in ellipticity suggests alterations in the secondary structure of MARK4 upon ibuprofen binding. The binding energy from docking was obtained as −7.0 kcal/mol. Ibuprofen was docked within the ATP or inhibitor binding site, with two hydrogen bonds. MD simulations confirmed the dynamic stability of the MARK4–ibuprofen complex over 100 ns. The complex retained overall compactness, with nominal increases in RMSD and RMSF relative to the apo protein. The findings demonstrate the potential of ibuprofen to inhibit MARK4 ATPase activity, which may further guide drug discovery.
SN - 2218-273X
ER -